Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Cariou

Showing results (191-200 of 311) with videos related to

Pageof 32
Sort By:
Diabetes, Obesity & Metabolism|August 4, 2016
Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trialsHenry Ginsberg, Bertrand Cariou, Trevor Orchard, et al.
Diabetes Care|June 26, 2018
HbA<sub>1c</sub> and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 StudyThomas Danne, Bertrand Cariou, Phillip Banks, et al.
Diabetes Care|March 6, 2019
Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem ProgramThomas Danne, Bertrand Cariou, John B Buse, et al.
Journal of Diabetes and Its Complications|June 9, 2016
Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trialsDaisuke Yabe, Anu Ambos, Bertrand Cariou, et al.
Cardiovascular Diabetology|June 10, 2022
Nutritional biomarkers and heart failure requiring hospitalization in patients with type 2 diabetes: the SURDIAGENE cohortMatthieu Wargny, Mikaël Croyal, Stéphanie Ragot, et al.
Cardiovascular Diabetology|February 10, 2020
Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterolHelen M Colhoun, Lawrence A Leiter, Dirk Müller-Wieland, et al.
Plos One|July 23, 2013
A standardized vascular disease health check in europe: a cost-effectiveness analysisC Andy Schuetz, Peter Alperin, Swathi Guda, et al.
Diabetes Care|August 28, 2020
Type 1 Diabetes in People Hospitalized for COVID-19: New Insights From the CORONADO StudyMatthieu Wargny, Pierre Gourdy, Lisa Ludwig, et al.
The Journal of Clinical Endocrinology and Metabolism|April 18, 2020
Plasma Trimethylamine N-Oxide and Risk of Cardiovascular Events in Patients With Type 2 DiabetesMikael Croyal, Pierre-Jean Saulnier, Audrey Aguesse, et al.
Diabetes Technology & Therapeutics|July 24, 2019
Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 DiabetesThomas Danne, Jeremy Pettus, Andrea Giaccari, et al.
Pageof 32

Showing results (191-200 of 311) with videos related to

Sort By:
Pageof 32
Diabetes, Obesity & Metabolism|August 4, 2016
Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trialsHenry Ginsberg, Bertrand Cariou, Trevor Orchard, et al.
Diabetes Care|June 26, 2018
HbA<sub>1c</sub> and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 StudyThomas Danne, Bertrand Cariou, Phillip Banks, et al.
Diabetes Care|March 6, 2019
Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem ProgramThomas Danne, Bertrand Cariou, John B Buse, et al.
Journal of Diabetes and Its Complications|June 9, 2016
Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trialsDaisuke Yabe, Anu Ambos, Bertrand Cariou, et al.
Cardiovascular Diabetology|June 10, 2022
Nutritional biomarkers and heart failure requiring hospitalization in patients with type 2 diabetes: the SURDIAGENE cohortMatthieu Wargny, Mikaël Croyal, Stéphanie Ragot, et al.
Cardiovascular Diabetology|February 10, 2020
Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterolHelen M Colhoun, Lawrence A Leiter, Dirk Müller-Wieland, et al.
Plos One|July 23, 2013
A standardized vascular disease health check in europe: a cost-effectiveness analysisC Andy Schuetz, Peter Alperin, Swathi Guda, et al.
Diabetes Care|August 28, 2020
Type 1 Diabetes in People Hospitalized for COVID-19: New Insights From the CORONADO StudyMatthieu Wargny, Pierre Gourdy, Lisa Ludwig, et al.
The Journal of Clinical Endocrinology and Metabolism|April 18, 2020
Plasma Trimethylamine N-Oxide and Risk of Cardiovascular Events in Patients With Type 2 DiabetesMikael Croyal, Pierre-Jean Saulnier, Audrey Aguesse, et al.
Diabetes Technology & Therapeutics|July 24, 2019
Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 DiabetesThomas Danne, Jeremy Pettus, Andrea Giaccari, et al.
Pageof 32